Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | PPARA | Q07869 | 3/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL6325287 | 0.84 | ALOX5 (0.58) | CYP3A4MEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL2554889 | 0.82 | ALDH1A1 (0.63) | CYP3A4MEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL29368253 | 0.82 | ALDH1A1 (0.63) | CYP3A4MEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL6325283 | 0.82 | PTGS1 (0.71) | CYP3A4MEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL6323578 | 0.81 | ALOX5 (0.66) | CYP3A4MEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL5199599 | 0.81 | MEN1 (0.64) | CYP3A4MEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL31438938 | 0.81 | MEN1 (0.64) | CYP3A4MEN1KMT2ATDP1L3MBTL1 | |
| Eugenol SCHEMBL4652636 | 0.81 | ALDH1A1 (0.70) | CYP3A4MEN1KMT2ATDP1L3MBTL1 | |
| Eugenol SCHEMBL28141128 | 0.78 | ALDH1A1 (0.65) | CYP3A4MEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL21749561 | 0.78 | NPC1 (0.57) | CYP3A4MEN1KMT2ATDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2555763-A1 | VIRAL INHIBITOR COMPOSITIONS FOR IN VIVO THERAPEUTIC USE COMPRISING A COMBINATION OF (-) -CARVONE, GERANIOL AND A FURTHER ESSENTIAL OIL COMPONENT | Cesa Alliance S.A. (LU) | 2013-02-13 | — | — | EP | claimed |
| WO-2011117424-A1 | VIRAL INHIBITOR COMPOSITIONS FOR IN VIVO THERAPEUTIC USE COMPRISING A COMBINATION OF (-) -CARVONE, GERANIOL AND A FURTHER ESSENTIAL OIL COMPONENT | CESA ALLIANCE S.A. (LU) | 2011-09-29 | — | — | WO | claimed |
| US-8980945-B2 | Viral inhibitor compositions for in vivo therapeutic use comprising a combination of (−)-carvone, geraniol and a further essential oil component | Cessa Alliance (LU) | 2015-03-17 | — | — | US | disclosed |
| US-8883859-B1 | Viral inhibitor compositions for in vivo therapeutic use comprising a combination of (-) -carvone, geraniol and a further essential oil component | CESA ALLIANCE S.A. (LU) | 2014-11-11 | — | — | US | disclosed |
| EP-2555763-B1 | VIRAL INHIBITOR COMPOSITIONS FOR IN VIVO THERAPEUTIC USE COMPRISING A COMBINATION OF (-)-CARVONE, (+)-CARVONE, GERANIOL AND A FURTHER ESSENTIAL OIL COMPONENT | CESA ALLIANCE SA (LU) | 2014-04-30 | — | — | EP | disclosed |
| US-20130225676-A1 | VIRAL INHIBITOR COMPOSITIONS FOR IN VIVO THERAPEUTIC USE COMPRISING A COMBINATION OF (-) -CARVONE, GERANIOL AND A FURTHER ESSENTIAL OIL COMPONENT | CESA ALLIANCE S.A. (LU) | 2013-08-29 | — | — | US | disclosed |
| US-4372835-A | Silane-functionalized ultraviolet screen precursors | GENERAL ELECTRIC CO. (US) | 1983-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225676-A1 | VIRAL INHIBITOR COMPOSITIONS FOR IN VIVO THERAPEUTIC USE COMPRISING A COMBINATION OF (-) -CARVONE, GERANIOL AND A FURTHER ESSENTIAL OIL COMPONENT | MED1, POLRMT, MED25 | CYP3A4 1732/4885MEN1 3519/4885KMT2A 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.